Correlation Between Viracta Therapeutics and Opus Genetics,

Can any of the company-specific risk be diversified away by investing in both Viracta Therapeutics and Opus Genetics, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Viracta Therapeutics and Opus Genetics, into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Viracta Therapeutics and Opus Genetics,, you can compare the effects of market volatilities on Viracta Therapeutics and Opus Genetics, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Viracta Therapeutics with a short position of Opus Genetics,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Viracta Therapeutics and Opus Genetics,.

Diversification Opportunities for Viracta Therapeutics and Opus Genetics,

0.27

Correlation Coefficient

Viracta Therapeutics  Opus Genetics,

Modest diversification

The 3 months correlation between Viracta and Opus is 0.27. Overlapping area represents the amount of risk that can be diversified away by holding Viracta Therapeutics and Opus Genetics, in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Opus Genetics, and Viracta Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Viracta Therapeutics are associated (or correlated) with Opus Genetics,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Opus Genetics, has no effect on the direction of Viracta Therapeutics i.e., Viracta Therapeutics and Opus Genetics, go up and down completely randomly.

Pair Corralation between Viracta Therapeutics and Opus Genetics,

Given the investment horizon of 90 days Viracta Therapeutics is expected to under-perform the Opus Genetics,. In addition to that, Viracta Therapeutics is 1.55 times more volatile than Opus Genetics,. It trades about -0.07 of its total potential returns per unit of risk. Opus Genetics, is currently generating about -0.03 per unit of volatility. If you would invest  351.00  in Opus Genetics, on December 2, 2024 and sell it today you would lose (248.00) from holding Opus Genetics, or give up 70.66% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	96.77%
Values	Daily Returns

Viracta Therapeutics  vs.  Opus Genetics,

Viracta Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Viracta Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Opus Genetics,

Risk-Adjusted Performance

Very Weak

Over the last 90 days Opus Genetics, has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound basic indicators, Opus Genetics, is not utilizing all of its potentials. The latest stock price tumult, may contribute to shorter-term losses for the shareholders.

Pair Trading with Viracta Therapeutics and Opus Genetics,

The main advantage of trading using opposite Viracta Therapeutics and Opus Genetics, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Viracta Therapeutics position performs unexpectedly, Opus Genetics, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Opus Genetics, will offset losses from the drop in Opus Genetics,'s long position.

The idea behind Viracta Therapeutics and Opus Genetics, pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.